Megan Johnson, NP
Nurse Practitioner · Marshfield, WINPI 1891090387
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $3,772 of the $6,157 with a category attached, or 61.3%. 21 manufacturers reported payments, led by Boston Scientific at 28.6% of the total. Reporting peaked in 2023 at $3,006 and has fallen 79.9% since, to $603 in 2025. Among nurse practitioner clinicians in WI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 76 payments — averaging $81.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$2K
- AstraZeneca$2K
- Abbott$1K
- Boehringer Ingelheim$179
- Pfizer$140
- E.r. Squibb & Sons, L.L.C.$131
- plus $844 from 15 others
What the payments were for
- Travel & lodging$3,77261%
- Food & beverage$2,26537%
- Education$1192%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 5 | $1,758 |
| AstraZeneca(2 entities) | 10 | $1,640 |
| Abbott | 7 | $1,464 |
| Boehringer Ingelheim | 9 | $179 |
| Pfizer | 3 | $140 |
| E.r. Squibb & Sons, L.L.C. | 8 | $131 |
| Lexicon Pharmaceuticals, Inc. | 5 | $129 |
| Amgen | 4 | $107 |
| Novartis | 5 | $101 |
| Novo Nordisk | 2 | $98 |
| United Therapeutics Corporation | 1 | $92 |
| Johnson & Johnson(2 entities) | 4 | $77 |
| Merck | 4 | $70 |
| Bayer | 2 | $38 |
| Abiomed | 1 | $33 |
| Scpharmaceuticals Inc. | 1 | $26 |
| Olympus America Inc. | 1 | $17 |
| Daiichi Sankyo Inc. | 1 | $16 |
| Esperion Therapeutics, Inc. | 1 | $16 |
| Actelion Pharmaceuticals US, Inc. | 1 | $13 |
| Daxor Corporation | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- WATCHMAN Access System$1,758
- ULTOMIRIS$1,387
- CARDIOMEMS$1,309
- AVEIR$117
How this compares
$6,157 in reported general payments places this provider in the 95th percentile of 3,478 nurse practitioner providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 13 | $326,655 |
| EliquisApixaban | 298 | $283,286 |
| EntrestoSacubitril/Valsartan | 224 | $270,299 |
| JardianceEmpagliflozin | 279 | $256,994 |
| XareltoRivaroxaban | 90 | $102,884 |
| FarxigaDapagliflozin Propanediol | 103 | $101,404 |
| Repatha SureclickEvolocumab | 69 | $50,362 |
| MultaqDronedarone Hcl | 14 | $25,078 |
| WegovySemaglutide | 15 | $24,266 |
| OzempicSemaglutide | 23 | $19,224 |
| Bumetanide | 294 | $9,103 |
| Metoprolol Succinate | 595 | $8,251 |
| Potassium Chloride | 178 | $5,932 |
| VascepaIcosapent Ethyl | 11 | $4,905 |
| Amiodarone Hcl | 117 | $2,863 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Eliquis | $140 | $609,941311 claims |
| NovartisEntresto | $101 | $270,299224 claims |
| Boehringer IngelheimJardiance | $179 | $256,994279 claims |
| Johnson & JohnsonXarelto | $77 | $102,88490 claims |
| AstraZenecaFarxiga | $1,640 | $101,404103 claims |
| Novo NordiskWegovy, Ozempic | $98 | $43,49038 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,478 nurse practitioner providers in Wisconsin.
Other nurse practitioner in Marshfield
- Michelle AlikpalaMarshfield$12K
- Jodi StrongStevens Point$246K
- Jo Ellen FrawleyPrairie du Sac$194K
- Trisha WilcoxMilwaukee$174K
- Sally BowaGreen Bay$117K
- Christina SauldMilwaukee$111K
- Melissa WendellWausau$98K
- Nicole BarteltWaukesha$85K
- Kari FisherPrairie du Sac$57K
- Roxanne RadichAppleton$54K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.